Ramazan Dertli1, Mehmet Asil1, Murat Bıyık1, Ahmet Karakarcayıldız1, Muharrem Keskin1, Yusuf Kayar2, Müşerref Başdemirci3, Hüseyin Ataseven1. 1. Division of Gastroenterology, Department of Internal Medicine, Necmettin Erbakan University, Meram School of Medicine, Meram, Konya, Turkey. 2. Division of Gastroenterology, Department of Internal Medicine, Van Training and Research Hospital, Van, Turkey. 3. Department of Medical Genetics, Necmettin Erbakan University, Meram School of Medicine, Konya, Turkey.
Abstract
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the important causes of mortality due to malignancy. Toll-like receptors (TLRs) are very important in liver pathophysiology in terms of their roles in the innate immune system, such as the regulation of inflammation, wound healing, stimulation of adaptive immune responses, promotion of epithelial regeneration, and carcinogenesis. In this study, we planned to examine the role of TLR1 (rs4833095, rs5743551) and nucleotide-binding oligomerization domain (NOD2) (rs2066844, rs2066845, rs2066847) polymorphisms in the development of HCC and their effects on the clinical presentation of HCC patients. METHODS: Our study was designed prospectively. Cirrhotic and HCC patients who were followed up in our clinic between January 2015 and September 2018 were included in the study. Sex, age, cirrhosis etiology, Child-Pugh class, and MELD scores were recorded. TLR1 and NOD2 polymorphisms were studied by the PCR method. RESULTS: HCC developed in 88 (31.4%) of the 280 patients who were followed up, either during the recruitment phase of our study or during the follow-up. The mean follow-up time of our patient group was 17.04 ± 11.72 months, and the mean follow-up time of HCC patients was 12.09 ± 10.26 months. TLR1 (rs5743551) polymorphism was associated with HCC development (P = .003). TLR1 (rs5743551) and NOD2 (rs2066844) polymorphisms were associated with the development of spontaneous bacterial peritonitis (SBP) in the HCC patient group (P = .013 and P = .021, respectively). CONCLUSION: We think that increased bacterial translocation in cirrhotic patients may contribute to HCC development by causing chronic inflammation, especially in patients with TLR 1 (rs5743551) polymorphism.
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the important causes of mortality due to malignancy. Toll-like receptors (TLRs) are very important in liver pathophysiology in terms of their roles in the innate immune system, such as the regulation of inflammation, wound healing, stimulation of adaptive immune responses, promotion of epithelial regeneration, and carcinogenesis. In this study, we planned to examine the role of TLR1 (rs4833095, rs5743551) and nucleotide-binding oligomerization domain (NOD2) (rs2066844, rs2066845, rs2066847) polymorphisms in the development of HCC and their effects on the clinical presentation of HCC patients. METHODS: Our study was designed prospectively. Cirrhotic and HCC patients who were followed up in our clinic between January 2015 and September 2018 were included in the study. Sex, age, cirrhosis etiology, Child-Pugh class, and MELD scores were recorded. TLR1 and NOD2 polymorphisms were studied by the PCR method. RESULTS: HCC developed in 88 (31.4%) of the 280 patients who were followed up, either during the recruitment phase of our study or during the follow-up. The mean follow-up time of our patient group was 17.04 ± 11.72 months, and the mean follow-up time of HCC patients was 12.09 ± 10.26 months. TLR1 (rs5743551) polymorphism was associated with HCC development (P = .003). TLR1 (rs5743551) and NOD2 (rs2066844) polymorphisms were associated with the development of spontaneous bacterial peritonitis (SBP) in the HCC patient group (P = .013 and P = .021, respectively). CONCLUSION: We think that increased bacterial translocation in cirrhotic patients may contribute to HCC development by causing chronic inflammation, especially in patients with TLR 1 (rs5743551) polymorphism.
Authors: Jorge Henao-Mejia; Eran Elinav; Christoph A Thaiss; Paula Licona-Limon; Richard A Flavell Journal: J Autoimmun Date: 2013-09-24 Impact factor: 7.094
Authors: Murat M M Harputluoglu; Ramazan Dertli; Baris Otlu; Ulvi Demirel; Ozkan Yener; Yilmaz Bilgic; Mehmet Ali Erdogan; Yahya Atayan; Yasir Furkan Cagin Journal: Dig Dis Sci Date: 2016-01-02 Impact factor: 3.199
Authors: Qiang Zhu; Li Zou; Kumaravelu Jagavelu; Douglas A Simonetto; Robert C Huebert; Zhi-Dong Jiang; Herbert L DuPont; Vijay H Shah Journal: J Hepatol Date: 2011-12-13 Impact factor: 25.083
Authors: Victoria L Stevens; Ann W Hsing; Jeffrey T Talbot; Siqun Lilly Zheng; Jielin Sun; Jinbo Chen; Michael J Thun; Jianfeng Xu; Eugenia E Calle; Carmen Rodriguez Journal: Int J Cancer Date: 2008-12-01 Impact factor: 7.396